Ocular Therapeutix stock hits 52-week high at $11.78

Ocular Therapeutix Inc . (NASDAQ:OCUL) stock reached a 52-week high, climbing to $11.78, with InvestingPro data showing the stock currently trading above its Fair Value amid strong momentum. This milestone reflects a significant upward trend for the company’s shares, which have experienced a 43.48% increase over the past year and an impressive 44.74% gain in the last six months. The stock’s rise to this new high has caught analysts’ attention, with price targets ranging from $14 to $22, though technical indicators suggest overbought conditions. The company maintains a "FAIR" Financial Health score according to InvestingPro analysis. As Ocular Therapeutix continues to advance its innovative therapeutic solutions, the stock’s recent performance highlights its position in the biotechnology sector. Discover more insights about OCUL and access the comprehensive Pro Research Report, along with 14 additional ProTips, exclusively on InvestingPro.

In other recent news, Ocular Therapeutix reported its first-quarter earnings for 2025, revealing a revenue of $10.6 million, which did not meet the projected $17.4 million by analysts at Raymond (NSE:RYMD) James. The company also posted a diluted earnings per share (EPS) of $(0.38), falling short of the expected $(0.30). The revenue decline was largely due to a decrease in sales of its product Dextenza, influenced by pricing adjustments and changes in stocking patterns. In contrast, the company has made significant progress in its clinical trials, with the SOL-R registrational trial nearing completion. This trial, along with SOL-1, aims to evaluate the effectiveness of AXPAXLI in treating wet Age-related Macular Degeneration. Analysts at H.C. Wainwright and Clear Street have maintained a Buy rating for the company, with price targets of $15 and $18, respectively. The swift enrollment for the SOL-R study has been noted as a positive sign of the medical community’s interest in AXPAXLI. Raymond James continues to hold a Strong Buy rating with a target of $19, despite the earnings miss. These developments highlight both challenges and potential opportunities for Ocular Therapeutix moving forward.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.